# A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene

Source: https://onco.cc/trials/nct04395677/  
OnCo record `nct04395677` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of AB-106 in non-small-cell lung cancer, run by Nuvation Bio Inc., active and no longer recruiting.

## Summary

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene is a phase 2 interventional study registered as NCT04395677 by Nuvation Bio Inc., with 173 participants enrolled, started 2020-07-07 and due to reach its primary completion in 2024-06-07. Interventions recorded: AB-106.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04395677
- Phase: 2
- Setting: A Multicenter, Open Label, Single Arm Phase 2 Study of AB-106 in the Treatment of Locally Advanced and Metastatic NSCLC
- Sponsor: Nuvation Bio Inc.
- Enrolled: 173

## Sources

- ClinicalTrials.gov NCT04395677: https://clinicaltrials.gov/study/NCT04395677

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Nuvation Bio](https://onco.cc/companies/nuvation-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct04395677.json